0K05 Stock Overview Through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Medifast, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Medifast Historical stock prices Current Share Price US$17.06 52 Week High US$67.05 52 Week Low US$16.57 Beta 1.18 1 Month Change -10.89% 3 Month Change -7.30% 1 Year Change -73.75% 3 Year Change -92.24% 5 Year Change -80.62% Change since IPO -75.96%
Recent News & Updates
New minor risk - Share price stability Dec 19
Investor sentiment deteriorates as stock falls 16% Dec 16
Now 21% undervalued Dec 12
Third quarter 2024 earnings released: EPS: US$0.10 (vs US$2.12 in 3Q 2023) Nov 05
Medifast, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024 Nov 05
Medifast, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 22 See more updates
New minor risk - Share price stability Dec 19
Investor sentiment deteriorates as stock falls 16% Dec 16
Now 21% undervalued Dec 12
Third quarter 2024 earnings released: EPS: US$0.10 (vs US$2.12 in 3Q 2023) Nov 05
Medifast, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024 Nov 05
Medifast, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 22
New major risk - Revenue and earnings growth Aug 07
New minor risk - Profit margin trend Aug 06
Second quarter 2024 earnings released: US$0.75 loss per share (vs US$2.78 profit in 2Q 2023) Aug 06
Medifast, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 23
Now 43% overvalued Jul 03
Now 46% overvalued Jul 02
Now 52% overvalued Jul 01
Now 21% overvalued Jun 19
Investor sentiment deteriorates as stock falls 15% Jun 08
Investor sentiment deteriorates as stock falls 24% May 06
New major risk - Revenue and earnings growth Apr 30
First quarter 2024 earnings released: EPS: US$0.76 (vs US$3.68 in 1Q 2023) Apr 30
Now 22% overvalued Apr 30
Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2024 Apr 30
Medifast, Inc. to Report Q1, 2024 Results on Apr 29, 2024 Apr 16
Investor sentiment deteriorates as stock falls 16% Apr 05
Independent Director recently sold US$109k worth of stock Mar 14
New major risk - Revenue and earnings growth Feb 22
Full year 2023 earnings released: EPS: US$9.13 (vs US$12.82 in FY 2022) Feb 21
Medifast Provides Earnings Guidance for the First Quarter of 2024 Feb 21
Medifast, Inc. to Report Q4, 2023 Results on Feb 20, 2024 Feb 07
Investor sentiment deteriorates as stock falls 16% Jan 18
New minor risk - Share price stability Jan 17
Now 20% undervalued after recent price drop Nov 07
Medifast, Inc. Provides Earnings Guidance for the Full Year 2023 Nov 07
New minor risk - Insider selling Oct 31
Medifast, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 24
Medifast, Inc. Announces Optavia Active Now Available Sep 14
Medifast, Inc. Declares Quarterly Cash Dividend, Payable on November 7, 2023 Sep 08
Medifast, Inc. Provides Earnings Guidance for the Third Quarter 2023 Aug 09
Second quarter 2023 earnings released: EPS: US$2.78 (vs US$3.45 in 2Q 2022) Aug 08
Medifast Unveils New Product Line, Optavia Active Jul 28
Medifast, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Jul 25
Now 20% undervalued after recent price drop Jul 22
Now 22% undervalued after recent price drop Jun 28
Medifast, Inc. Declares Quarterly Cash Dividend, Payable on August 8, 2023 Jun 16
Medifast, Inc., Annual General Meeting, Jun 14, 2023 May 26
First quarter 2023 earnings released: EPS: US$3.68 (vs US$3.62 in 1Q 2022) May 03
Now 26% undervalued after recent price drop May 03
Full year 2022 earnings released: EPS: US$12.82 (vs US$14.01 in FY 2021) Feb 22
Medifast, Inc. to Report Q4, 2022 Results on Feb 21, 2023 Feb 08
Upcoming dividend of US$1.64 per share Dec 12
Medifast, Inc. Announces Quarterly Dividend, Payable on February 7, 2023 Dec 09
Insufficient new directors Nov 16
Now 22% undervalued after recent price drop Nov 09
Third quarter 2022 earnings released: EPS: US$3.30 (vs US$3.59 in 3Q 2021) Nov 05
Medifast, Inc. Revises Earnings Guidance for the Year 2022 Nov 04
Medifast, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 21
Upcoming dividend of US$1.64 per share Sep 12
Medifast Announces Quarterly Dividend, Payable on November 8, 2022 Sep 09
Now 20% undervalued after recent price drop Aug 25
Lead Independent Director recently bought US$499k worth of stock Aug 13
Investor sentiment deteriorated over the past week Aug 10
Second quarter 2022 earnings released: EPS: US$3.45 (vs US$4.00 in 2Q 2021) Aug 04
Medifast, Inc. Revises Earnings Guidance for the Full-Year of 2022 Aug 04
Medifast Announces New Scientific Advisory Board Appointments Jul 22
Medifast, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 21
Medifast, Inc.(NYSE:MED) dropped from Russell 2000 Dynamic Index Jun 26
Upcoming dividend of US$1.64 per share Jun 20
Medifast, Inc. Announces Quarterly Dividend, Payable on August 8, 2022 Jun 17
Executive Chairman & CEO recently bought US$79k worth of stock May 12
First quarter 2022 earnings released May 03
Medifast, Inc. Revises Earnings Guidance for the Full-Year of 2022 May 03
Insufficient new directors May 03 Medifast, Inc., Annual General Meeting, Jun 15, 2022
Medifast, Inc. to Report Q1, 2022 Results on May 02, 2022 Apr 19
Insider recently sold US$200k worth of stock Mar 15
Medifast, Inc. Provides Earnings Guidance for the Full-Year 2022 Feb 24
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Medifast, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 12
Upcoming dividend of US$1.42 per share Dec 13
Insufficient new directors Dec 06
Third quarter 2021 earnings released: EPS US$3.59 (vs US$2.93 in 3Q 2020) Nov 06
Independent Director recently sold US$149k worth of stock Aug 26
VP of Finance & Chief Accounting Officer Stephen Johnson has left the company Aug 11
Medifast, Inc. Provides Earnings Guidance for 2021 Aug 05
Second quarter 2021 earnings released: EPS US$4.00 (vs US$1.86 in 2Q 2020) Aug 05
Upcoming dividend of US$1.42 per share Jun 15
Independent Director recently sold US$310k worth of stock May 24
Investor sentiment improved over the past week May 11
First quarter 2021 earnings released: EPS US$3.49 (vs US$1.57 in 1Q 2020) May 06
Medifast, Inc. Announces Earnings Guidance for the Full Year 2021 May 05
Upcoming Dividend of US$1.42 Per Share Mar 22
Medifast, Inc. Announces Quarterly Dividend, Payable on May 6, 2021 Mar 19
Full year 2020 earnings released: EPS US$8.74 (vs US$6.62 in FY 2019) Feb 27
Revenue beats expectations Feb 27
Medifast, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 12
Investor sentiment improved over the past week Dec 17
Medifast, Inc. Announces Board Changes Dec 11
Medifast Appoints Lauren Walker as Executive Vice President, Supply Chain Operations Sep 22
First half earnings released Aug 11 Shareholder Returns 0K05 GB Personal Products GB Market 7D -2.5% 0.2% 1.3% 1Y -73.8% 18.1% 4.3%
See full shareholder returns
Return vs Market: 0K05 underperformed the UK Market which returned 4.3% over the past year.
Price Volatility Is 0K05's price volatile compared to industry and market? 0K05 volatility 0K05 Average Weekly Movement 7.2% Personal Products Industry Average Movement 3.6% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0K05's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0K05's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform.
Show more Medifast, Inc. Fundamentals Summary How do Medifast's earnings and revenue compare to its market cap? 0K05 fundamental statistics Market cap US$184.17m Earnings (TTM ) US$7.33m Revenue (TTM ) US$674.48m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0K05 income statement (TTM ) Revenue US$674.48m Cost of Revenue US$176.70m Gross Profit US$497.77m Other Expenses US$490.45m Earnings US$7.33m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/03 08:48 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Medifast, Inc. is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Anand Vankawala Avondale Partners Kara Anderson B. Riley Securities, Inc. Scott Van Winkle Canaccord Genuity
Show 9 more analysts 
